NBE Therapeutics was founded in 2012 by Dr. Ulf Grawunder, a seasoned biotech entrepreneur and former CEO/CSO of 4-Antibody, Switzerland, that was recently sold to U.S.-based Agenus (AGEN). Ulf Grawunder, CEO of NBE-Therapeutics, is an expert in the field of fully human therapeutic antibody discovery and engineering and has developed two novel patent-pending technologies for the discovery of fully human antibodies and the generation of next-generation antibody drug conjugates (ADCs).
Early in 2013, Dr. Roger Beerli, an expert in the field of therapeutic antibody discovery by mammalian cell based antibody library display, joined the management team of NBE-Therapeutics as VP Research and Development. It is the vision of NBE-Therapeutics is to develop next-generation antibody drug conjugates (ADCs) improving therapy options for cancer patients. Since the beginning of 2013 the company is financially backed by the Boehringer Ingelheim Venture Fund, leading an investors syndicate also including additional private life-science investors.
- Barcelona, 2017-05-18 - NBE-Therapeutics invited to present at the 2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics
- London, 2017-05-15 - NBE-Therapeutics will present at the 2nd Annual Advances in Immuno-Oncology Congress, London, U.K.
- Boston, MA, USA, 2017-05-02 - NBE-Therapeutics to present update on R&D activities at 2017-PEGS conference